Sten R.. Sorensen

Sten R. Sörensen is a seasoned executive with extensive experience spanning the pharmaceutical, biotechnology, and finance industries. Currently serving as the CEO of Cereno Scientific, he leads a publicly listed biotech company that is pioneering disease-modifying treatments for rare cardiovascular and pulmonary diseases. The company advances an epigenetic HDAC inhibitor platform designed to target underlying disease mechanisms with potential applicability across multiple cardiopulmonary indications. The aim is to lead a shift in the treatment paradigm offering disease-modifying treatments that can slow down, halt and reverse disease progression. The pipeline comprises three drug candidates of which two are in clinical-stage (Phase IIb and Phase I). Previously, Sörensen has held senior roles in major pharmaceutical companies, including Head of International Marketing Operations at Monsanto, US, and Global Marketing Director for Cardiovascular Secondary Prevention Products at AstraZeneca, Sweden. His initiatives at AstraZeneca resulted in two groundbreaking preventative survival studies in heart failure, revolutionizing treatment standards and significantly improving patient outcomes. Additionally, Sörensen serves as the Chairman of SARomics Biostructure and is a board member of SynAct Pharma and Cereno Scientific.